Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets - GBI Research Reports

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets - GBI Research Reports
Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
Published Aug 21, 2010
125 pages — Published Aug 21, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's Therapeutic Analysis report, 'Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets', provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

- Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).
- Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
- Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gap

  
Source:
Document ID
GBIHC033MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Executive Summary12
2 Table of Contents37
2.1 List of Tables52
2.2 List of Figures73
3 Global Urological Disorders Market: Introduction102
3.1 GBI Research Report Guidance111
4 Global Urological Disorders Market: Market Overview1212
4.1 Introduction121
4.2 Revenue Forecasts for the Global Urological Disorders Market131
4.2.1 Sales Value131
4.2.2 Annual Cost of Therapy141
Treatment Usage Patterns152
4.2.3.1 Diseased Population171
4.2.3.2 Treatment Seeking Population181
4.2.3.3 Diagnosed Population191
4.2.3.4 Prescription Population201
4.2.4 Generics Share in the Global Urological Disorders Market202
4.3 Urological Disorders Market Drivers221
4.3.1 Steady Increase in the UI and BPH Prevalence Population221
4.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH221
4.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable 221
4.4 Urological Disorders Market Restraints231
4.4.1 Unwillingness to Seek Medical Help for UI231
4.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues231
4.4.3 Non Pharmacological Therapy Recommended for UI and BPH 231
5 Global Urological Disorders Market: Therapeutic Landscape2440
5.1 Benign Prostatic Hyperplasia Market241
5.1.1 Introduction241
5.1.2 Sales Value242
5.1.3 Annual Cost of Therapy261
5.1.4 Treatment Usage Patterns271
5.1.4.1 Diseased Population281
5.1.4.2 Treatment Seeking Population291
5.1.4.3 Diagnosed Population301
5.1.4.4 Prescription Population311
5.1.5 Market Share by Geography323
5.1.6 Generics Share of the Global BPH Market351
5.2 Urinary Incontinence (UI) Market361
5.2.1 Introduction361
5.2.2 Sales Value372
5.2.3 Annual Cost of Therapy391
5.2.4 Treatment Usage Patterns401
5.2.4.1 Diseased Population411
5.2.4.2 Treatment Seeking Population421
5.2.4.3 Diagnosed Population431
5.2.4.4 Prescription Population 441
5.2.5 Market Share by Geography454
5.2.6 Generics Share in the Global UI Market492
5.3 Urinary Tract Infections Market511
5.3.1 Introduction511
5.3.2 Sales Value512
5.3.3 Annual Cost of Therapy531
5.3.4 Treatment Usage Patterns541
5.3.4.1 Diseased Population551
5.3.4.2 Treatment Seeking Population561
5.3.4.3 Diagnosed Population571
5.3.4.4 Prescription Population 581
5.3.5 Market Share by Geography593
5.3.6 Generics Share of the Global UTI Market622
6 Global Urological Disorders Market: Geographical Landscape6426
6.1 Geographical Break-up643
6.2 The US671
6.2.1 Sales Value671
6.2.2 Annual Cost of Therapy681
6.2.3 Treatment Usage Patterns691
6.2.3.1 Diseased Population701
6.2.3.2 Treatment Seeking Population712
6.2.3.3 Diagnosed Population731
6.2.3.4 Prescription Population 741
6.3 Top Five Countries in Europe751
6.3.1 Sales Value751
6.3.2 Annual Cost of Therapy761
6.3.3 Treatment Usage Patterns772
6.3.3.1 Diseased Population791
6.3.3.2 Treatment Seeking Population801
6.3.3.3 Diagnosed Population811
6.3.3.4 Prescription Population 821
6.4 Japan831
6.4.1 Sales Value831
6.4.2 Annual Cost of Therapy841
6.4.3 Treatment Usage Patterns851
6.4.3.1 Diseased Population861
6.4.3.2 Treatment Seeking Population871
6.4.3.3 Diagnosed Population881
6.4.3.4 Prescription Population 891
7 Global Urological Disorders Market: Pipeline Analysis9011
7.1 Introduction901
7.1.1 Research and Development Pipeline UI912
7.1.2 Research and Development Pipeline BPH932
7.1.3 Research and Development Pipeline UTI952
7.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market971
7.2.1 Botulinum Toxin A 971
7.2.1.1 Introduction971
7.2.1.2 Efficacy971
7.2.1.3 Safety971
7.2.1.4 Clinical Study Details971
7.2.2 YM178981
7.2.2.1 Introduction981
7.2.2.2 Efficacy981
7.2.2.3 Safety981
7.2.2.4 Clinical Study Details981
7.2.3 NX-1207 981
7.2.3.1 Introduction981
7.2.3.2 Efficacy981
7.2.3.3 Safety Profile991
7.2.3.4 Clinical Study Details 991
7.2.4 PRX302991
7.2.4.1 Introduction991
7.2.4.2 Efficacy991
7.2.4.3 Safety991
7.2.4.4 Clinical Study Details 991
7.2.5 NXL104/ceftazidime1001
7.2.5.1 Introduction1001
7.2.5.2 Efficacy1001
7.2.5.3 Safety1001
7.2.5.4 Clinical Study Details1001
8 Global Urological Disorders Market: Competitive Landscape1019
8.1 Market Share Analysis: Urological Disorders1012
8.2 Competitive Profiling 1031
8.2.1 Astellas Pharma1031
8.2.1.1 Product Portfolio1031
8.2.2 Johnson and Johnson (J&J)1041
8.2.2.1 Product Portfolio1051
8.2.3 Pfizer1061
8.2.3.1 Product Portfolio1061
8.2.4 GlaxoSmithKilne (GSK)1071
8.2.4.1 Product Portfolio1071
8.2.5 Sanofi-Aventis1081
8.2.5.1 Product Portfolio1091
9 Global Urological Disorders Market: Strategic Consolidations11010
9.1 Overview1102
9.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter &Gamble in October 20091121
9.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 20071121
9.1.3 Biofusion Acquires Minority Stake in Muscagen in November 20061121
9.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 20061121
9.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 20051121
9.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 20041121
9.2 R&D Licensing Agreements 1131
Deals by Indication1131
9.2.2 Deals by Phase1141
9.2.3 Deals by Geography1141
9.2.4 Deals by Licensing Type1151
9.2.5 Deals by Value ($)1151
9.2.6 Phase I1161
9.2.6.1 MN-2461161
9.2.7 Phase II1171
9.2.7.1 PRX3021171
9.2.7.2 GRT 2031171
9.2.7.3 PSD 5061171
9.2.8 Approved1181
9.2.8.1 Silodyx1181
9.2.8.2 Silodosin1181
9.2.8.3 Urief1181
9.2.8.4 SANCTURA XR1181
9.2.8.5 Kentera1191
10 Global Urological Disorders Market: Appendix1206
10.1 Market Definitions1201
10.2 Abbreviations1201
10.3 Research Methodology1214
10.3.1 Coverage 1211
10.3.2 Secondary Research1211
10.3.3 Primary Research1221
10.3.4 Forecasts1221
10.3.4.1 Epidemiology-based Forecasting1222
10.3.5 Expert Panel Validation1241
10.4 Contact Us1251
10.5 Disclaimer1251
10.6 Sources1251

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets" Aug 21, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Urological-Disorders-Therapeutics-to-2016-Increasing-Awareness-and-Aging-Population-will-Drive-the-Benign-Prostatic-Hyperplasia-and-Urinary-Incontinence-Markets-2115-74>
  
APA:
GBI Research Reports. (2010). Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets Aug 21, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Urological-Disorders-Therapeutics-to-2016-Increasing-Awareness-and-Aging-Population-will-Drive-the-Benign-Prostatic-Hyperplasia-and-Urinary-Incontinence-Markets-2115-74>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.